Infinium Pharmachem is a specialist that has built an entire business around a single, scarce element: iodine. Incorporated in Gujarat in 2003, the company spent two decades moving from making simple iodine derivatives to a fully integrated model that now reaches all the way back to extracting iodine from underground brine in Oklahoma. The recurring approach is vertical control - securing the raw material, mastering the difficult chemistry in between, and then stepping forward into higher-value finished drugs - so that it captures margin at every link in the chain rather than buying from middlemen. # Business segments A single integrated engine built on iodine chemistry, stretching from raw-material extraction in the US through hundreds of derivatives to finished pharmaceutical ingredients - each stage feeding the next. ## 1. Iodine derivatives and APIs: the chemistry engine that turns a scarce mineral into medicine **The company makes over 220 iodine-based chemical building blocks and 19 active drug ingredients, selling them under its own brand to pharmaceutical and chemical customers across 30 countries - and it now secures its own iodine supply from a US joint venture.** - **A portfolio of rare molecules** - the catalogue spans more than 220 iodine derivatives and 19 APIs (Active Pharmaceutical Ingredients, the molecules that make a drug work), with derivatives contributing roughly 80-90% of revenue. Products range from laboratory reagents like N-iodosuccinimide to complex contrast-media intermediates such as ATIPA, where the company is one of only a handful of global players. - **Sold under its own name, not someone else's label** - the company operates a CRAMS model (Contract Research and Manufacturing Services) but sells specialized products under its own brand rather than as an anonymous contract manufacturer, often working under non-disclosure agreements for rare and confidential compounds. - **The raw material is the moat** - iodine is a scarce mineral found in commercial quantities in only three or four places on earth, with Chile controlling 60-70% of the market, and pricing is dictated by a handful of suppliers. To break that dependency, the company set up a joint venture in Oklahoma that extracts 99.9% pure medical-grade iodine from salt water, a byproduct of oil and gas operations, using air-desorption technology at minimal investment compared to conventional mining. The venture has a 30-year contract to supply its entire output - roughly 120 metric tonnes a year - to Infinium at arm’s-length prices, making the company immune to import-driven price spikes. - **Capacity built ahead of demand** - the main plant at Sojitra, Gujarat, was expanded and modernised during FY25 to an installed capacity of 1,800 metric tonnes per annum, against actual annual production of 293 metric tonnes. That low utilisation of about 20% still delivered a 26% return on capital employed in FY24, and utilisation is expected to rise as more iodine is consumed captively rather than sold as an intermediate. - **Quality credentials that open regulated markets** - the facility is WHO-GMP compliant and holds ISO 9001, ISO 22000, and ISO 14001 certifications, and it has received FDA India approval for API manufacturing, which means it can supply customers who make finished drugs for highly regulated markets. ## 2. Contrast media raw materials: the forward step into diagnostic imaging **The company has commissioned a dedicated facility to make the chemical precursors used in PET scans, MRI and X-ray contrast agents - a move that takes its existing iodine intermediates and processes them further into higher-value products.** - **From intermediate to finished raw material** - contrast media are the substances patients drink or are injected with before a scan to make organs visible, and they depend on iodine-based chemistry. Infinium already made the key intermediate ATIPA dichloride; the new unit, with a planned capital expenditure of Rs. 11 crore and construction commenced in July 2024 on a 1,114-square-metre plot adjacent to the existing plant, turns that intermediate into finished contrast-media raw materials. - **Commissioned and sampling** - the facility was declared operational in January 2026, pilot-scale production of ATIPA and ATIPA dichloride has begun, and commercial samples have already been offered to potential buyers. Discussions are underway with two leading API manufacturers for long-term supply contracts. - **Cost advantage through backward integration** - because the company makes its own iodine-based derivatives in-house, it can perform two or three additional chemical steps on its own raw materials rather than buying them from a supplier, giving it a structural cost edge over competitors who start further downstream. # Captive energy and raw-material security **The company runs two subsidiaries that function as internal utilities - one makes bio-coal to slash the fuel bill, the other extracts iodine from US brine to guarantee supply - turning volatile input costs into a controlled advantage.** - **Bio-coal from agricultural waste** - subsidiary Infinium Green Energy manufactures bio-coal from cellulosic farm waste at a plant in Jamnagar, Gujarat, producing 5,000 metric tonnes during FY25. The parent company consumes this bio-coal as a substitute for gas in its manufacturing, cutting its fuel cost by almost half, with any surplus sold on the open market. - **Solar power under construction** - a 1.1 MW DC ground-mounted solar project is being built at Village Ved, Gujarat, at an estimated cost of Rs. 4 crore, funded with 80% debt. Once commissioned, the electricity will be captively consumed by both the existing derivatives plant and the new contrast-media facility. # Group structure and partners **The parent company sits at the centre of four subsidiaries and a Japanese distribution alliance, each purpose-built to feed or sell into the iodine chemistry engine.** - **Infinium Pharmachem Ltd** is the listed parent, headquartered in Gujarat with its factory at GIDC Sojitra, and promoters hold just over 65% of the equity. - **Infinium Healthcare Private Limited** (51% subsidiary, acquired in August 2024 for Rs. 15.3216 crore in cash) was already a key raw-material supplier to the parent and is now being developed as a platform for API manufacturing and trading across therapeutic segments, using USFDA and WHO-GMP compliant partner facilities on a job-work basis. - **Infinium Green Energy Private Limited** (51% subsidiary) manufactures bio-coal and other renewable fuels in Jamnagar, meeting the parent’s energy needs and selling the remainder in the open market. - **Shanghai Tajilin Industrial Co. Limited** (51% joint venture in China) acts as an exclusive distributor, importing Infinium’s products from India and selling them across the Chinese market in pharmaceuticals, agrochemicals and electronics. - **K Sakai & Company, Japan** - a century-old chemical distributor with around 70 professionals - holds a five-year exclusive agreement to market Infinium’s entire iodine-derivative range in Japan, targeting customers in semiconductors, solar, electronics, pharmaceuticals and agrochemicals.